Lixte Cash Per Share from 2010 to 2025

LIXTW Stock  USD 0.03  0  2.86%   
Lixte Biotechnology Cash Per Share yearly trend continues to be fairly stable with very little volatility. Cash Per Share will likely drop to 0.44 in 2025. During the period from 2010 to 2025, Lixte Biotechnology Cash Per Share regression line of quarterly data had mean square error of  65.54 and geometric mean of  0.47. View All Fundamentals
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
0.4619022
Current Value
0.44
Quarterly Volatility
8.21796209
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lixte Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lixte Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 19.6 K, Other Operating Expenses of 6.1 M or EBITDA of 3.9 K, as well as many indicators such as Price To Sales Ratio of 56.09, Dividend Yield of 2.0E-4 or PTB Ratio of 5.8. Lixte financial statements analysis is a perfect complement when working with Lixte Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Lixte Biotechnology Correlation against competitors.

Latest Lixte Biotechnology's Cash Per Share Growth Pattern

Below is the plot of the Cash Per Share of Lixte Biotechnology Holdings over the last few years. It is Lixte Biotechnology's Cash Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lixte Biotechnology's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.10 X10 Years Trend
Slightly volatile
   Cash Per Share   
       Timeline  

Lixte Cash Per Share Regression Statistics

Arithmetic Mean3.57
Geometric Mean0.47
Coefficient Of Variation230.17
Mean Deviation4.00
Median1.40
Standard Deviation8.22
Sample Variance67.53
Range33.8389
R-Value0.31
Mean Square Error65.54
R-Squared0.09
Significance0.25
Slope0.53
Total Sum of Squares1,013

Lixte Cash Per Share History

2025 0.44
2024 0.46
2023 2.2
2022 33.84
2021 3.58
2020 4.5
2019 2.33

About Lixte Biotechnology Financial Statements

Lixte Biotechnology investors use historical fundamental indicators, such as Lixte Biotechnology's Cash Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lixte Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Per Share 0.46  0.44 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.